Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;36(9):2104-2115.
doi: 10.1002/mds.28624. Epub 2021 May 5.

Cortical [18 F]PI-2620 Binding Differentiates Corticobasal Syndrome Subtypes

Carla Palleis #  1   2 , Matthias Brendel #  3   4 , Anika Finze  3 , Endy Weidinger  1   2 , Kai Bötzel  1 , Adrian Danek  1 , Leonie Beyer  3 , Alexander Nitschmann  3 , Maike Kern  3 , Gloria Biechele  3 , Boris-Stephan Rauchmann  5   6 , Jan Häckert  6 , Matthias Höllerhage  7 , Andrew W Stephens  8 , Alexander Drzezga  9   10   11 , Thilo van Eimeren  9   10   12 , Victor L Villemagne  13 , Andreas Schildan  14 , Henryk Barthel  14 , Marianne Patt  14 , Osama Sabri  14 ; German Imaging Initiative for Tauopathies (GII4T); Peter Bartenstein  3   4 , Robert Perneczky  2   4   6   15 , Christian Haass  2   4   16 , Johannes Levin #  1   2   4 , Günter U Höglinger #  2   4   7
Affiliations

Cortical [18 F]PI-2620 Binding Differentiates Corticobasal Syndrome Subtypes

Carla Palleis et al. Mov Disord. 2021 Sep.

Abstract

Background: Corticobasal syndrome is associated with cerebral protein aggregates composed of 4-repeat (~50% of cases) or mixed 3-repeat/4-repeat tau isoforms (~25% of cases) or nontauopathies (~25% of cases).

Objectives: The aim of this single-center study was to investigate the diagnostic value of the tau PET-ligand [18 F]PI-2620 in patients with corticobasal syndrome.

Methods: Forty-five patients (71.5 ± 7.6 years) with corticobasal syndrome and 14 age-matched healthy controls underwent [18 F]PI-2620-PET. Beta-amyloid status was determined by cerebral β-amyloid PET and/or CSF analysis. Subcortical and cortical [18 F]PI-2620 binding was quantitatively and visually compared between β-amyloid-positive and -negative patients and controls. Regional [18 F]PI-2620 binding was correlated with clinical and demographic data.

Results: Twenty-four percent (11 of 45) were β-amyloid-positive. Significantly elevated [18 F]PI-2620 distribution volume ratios were observed in both β-amyloid-positive and β-amyloid-negative patients versus controls in the dorsolateral prefrontal cortex and basal ganglia. Cortical [18 F]PI-2620 PET positivity was distinctly higher in β-amyloid-positive compared with β-amyloid-negative patients with pronounced involvement of the dorsolateral prefrontal cortex. Semiquantitative analysis of [18 F]PI-2620 PET revealed a sensitivity of 91% for β-amyloid-positive and of 65% for β-amyloid-negative cases, which is in excellent agreement with prior clinicopathological data. Regardless of β-amyloid status, hemispheric lateralization of [18 F]PI-2620 signal reflected contralateral predominance of clinical disease severity.

Conclusions: Our data indicate a value of [18 F]PI-2620 for evaluating corticobasal syndrome, providing quantitatively and regionally distinct signals in β-amyloid-positive as well as β-amyloid-negative corticobasal syndrome. In corticobasal syndrome, [18 F]PI-2620 may potentially serve for a differential diagnosis and for monitoring disease progression. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Keywords: Alzheimer's disease; PET; corticobasal syndrome; four-repeat tauopathies; tau.

PubMed Disclaimer

References

    1. Hoglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. Mov Disord 2017;32(6):853-864.
    1. Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013;80(5):496-503.
    1. Ling H, O'sullivan SS, Holton JL, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 2010;133(Pt 7):2045-2057.
    1. Rösler TW, Tayaranian Marvian A, Brendel M, et al. Four-repeat tauopathies. Prog Neurobiol 2019;180:101644.
    1. Höglinger GU. Is it useful to classify progressive supranuclear palsy and corticobasal degeneration as different disorders? No. Mov Disord Clin Pract 2018;5(2):141-144.

Publication types

Substances

LinkOut - more resources